NRC Health (NASDAQ: NRC) is a Healthcare company in the Medical - Healthcare Information Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 77.49 | EPS (ttm) | 0.26 | Insider Own | - | Shs Outstand | 22.54M | Perf Week | 4.25% |
| Market Cap | 458.40M | Forward P/E | 18.32 | EPS next Y | 1.11 | Insider Trans | 0.03% | Shs Float | 11.84M | Perf Month | -6.31% |
| Enterprise Value | 545.10M | PEG | - | EPS next Q | 0.21 | Inst Own | - | Short Float | 4.40% | Perf Quarter | 8.60% |
| Income | 6.00M | P/S | 3.27 | EPS this Y | 252.00% | Inst Trans | - | Short Ratio | 4.25 | Perf Half Y | 27.68% |
| Sales | 139.99M | P/B | 68.36 | EPS next Y | 26.14% | ROA | 4.30% | Short Interest | 520.82K | Perf YTD | 8.36% |
| Book/sh | - | P/C | 15.17 | EPS next 5Y | 14.81% | ROE | 48.46% | 52W High | 24.19 -14.10% | Perf Year | 43.64% |
| Cash/sh | - | P/FCF | 21.18 | EPS past 3/5Y | -25.74% -18.54% | ROIC | 8.75% | 52W Low | 11.25 84.74% | Perf 3Y | -53.60% |
| Dividend Est. | 0.64 (3.08%) | EV/EBITDA | 23.30 | Sales past 3/5Y | -3.40% 0.59% | Gross Margin | 66.79% | Volatility | 4.00% 5.71% | Perf 5Y | -61.46% |
| Dividend TTM | 0.60 (2.89%) | EV/Sales | 3.89 | EPS Y/Y TTM | -75.96% | Oper. Margin | 10.53% | ATR (14) | 1.20 | Perf 10Y | 28.49% |
| Dividend Ex-Date | Sep 25, 2026 | Quick Ratio | 0.65 | Sales Y/Y TTM | -2.10% | Profit Margin | 4.18% | RSI (14) | 49.40 | Recom | 2.00 |
| Dividend Gr. 3/5Y | -14.77% 19.88% | Current Ratio | 0.65 | EPS Q/Q | 10.71% | SMA20 | -1.81% | Beta | 0.37 | Target Price | - |
| Payout | 216.92% | Debt/Eq | 13.75 | Sales Q/Q | 2.94% | SMA50 | -0.52% | Rel Volume | 1.13 | Prev Close | 20.34 |
| Employees | 357 | LT Debt/Eq | 5.36 | Earnings | Oct 26 | SMA200 | 14.36% | Avg Volume | 123.49K | Price | 20.78 |
| IPO Date | May 23, 2013 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 306.67% - | Net Debt/EBITDA | 3.71 | Volume | 139,259 | Change | 2.16% |
National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning. They offer advanced segmentation tools to analyze community needs, wants, and behaviors in real-time. Specialized health risk assessment tools are available to help clients pinpoint and support high-risk populations, fostering preventative care strategies and wellness initiatives. Similarly, transition management solutions assist in identifying and managing at-risk patients during care changes, aiming to reduce readmissions and ensure smooth, satisfactory transitions. NRC also offers transparency tools, empowering healthcare providers to present clear organizational information to consumers, thereby supporting informed decision-making. Furthermore, governance solutions are tailored for the leadership of non-profit hospitals and health systems, including boards of directors, executives, and physician leaders. Their clientele includes integrated health systems, post-acute care providers, and healthcare payer organizations. Established in 1981, National Research Corporation maintains its headquarters in Lincoln, Nebraska.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 140 | 137 | 143 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 47 | 60 | 57 | — | — | — | — | — | — | |
| Gross Profit | 93 | 77 | 86 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 62 | 55 | 45 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | 16 | 0 | 6 | — | — | — | — | — | — | |
| Operating Income | 16 | 23 | 35 | — | — | — | — | — | — | |
| Interest Expense | 4 | 5 | 3 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 0 | 0 | 0 | — | — | — | — | — | — | |
| Net Income Before Taxes | 8 | 18 | 33 | — | — | — | — | — | — | |
| Income Taxes | 3 | 6 | 8 | — | — | — | — | — | — | |
| Consolidated Net Income | 6 | 12 | 25 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 6 | 12 | 25 | — | — | — | — | — | — | |
| Net Income | 6 | 12 | 25 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.26 | 0.52 | 1.05 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.26 | 0.52 | 1.05 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.25 | 0.52 | 1.04 | — | — | — | — | — | — | |
| EBITDA | 24 | 30 | 41 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 83.12 | 36.10 | 16.96 | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.27 | 3.01 | 2.96 | — | — | — | — | — | — | |
| Gross Margin | 66.43 | 56.20 | 60.14 | — | — | — | — | — | — | |
| Operating Margin | 11.43 | 16.79 | 24.48 | — | — | — | — | — | — | |
| Net Margin | 4.29 | 8.76 | 17.48 | — | — | — | — | — | — | |
| Shares Outstanding | 22 | 22 | 24 | — | — | — | — | — | — | |
| Market Capitalization | 457 | 413 | 423 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| HARRISON SHANE R | EVP & Chief Financial Officer | Feb 17 '26 | Buy | 12.27 | 8,000 | 98,162 | 8,000 | Feb 19 |
| Hays Michael D. | Chairman | Jan 05 '26 | Option Exercise | 15.23 | 9,145 | 139,278 | 20,154 | Jan 07 |
| Hrdy Helen | EVP & Chief Operating Officer | Dec 15 '25 | Option Exercise | 15.23 | 12,346 | 188,030 | 151,762 | Dec 17 |
| Freeman Jordan Nicole | Chief Accounting Officer | Jul 31 '25 | Buy | 12.97 | 771 | 10,000 | 771 | Aug 04 |
| BEANS PATRICK E | 10% Owner | May 12 '25 | Buy | 13.59 | 2,500 | 33,974 | 35,003 | May 13 |
| Hays Michael D. | CEO & President | Jan 02 '25 | Option Exercise | 13.17 | 10,014 | 131,884 | 11,009 | Jan 06 |
| NUNNELLY JOHN N | Director | Mar 27 '24 | Option Exercise | 14.95 | 9,259 | 138,422 | 36,153 | Mar 29 |
| Common Property Trust | 10% Owner | Mar 01 '24 | Sale | 40.54 | 598,653 | 24,269,393 | 3,854,284 | Mar 05 |
| Amandla MK Trust | 10% Owner | Jan 05 '24 | Sale | 40.20 | 2,614 | 105,092 | 3,831,362 | Jan 08 |
| Amandla MK Trust | 10% Owner | Jan 04 '24 | Sale | 41.22 | 4,600 | 189,617 | 3,833,976 | Jan 08 |
| Common Property Trust | 10% Owner | Jan 03 '24 | Sale | 41.53 | 364,625 | 15,142,876 | 4,452,937 | Jan 05 |
| Amandla MK Trust | 10% Owner | Jan 03 '24 | Sale | 41.77 | 120,139 | 5,018,759 | 3,838,576 | Jan 04 |
| Hays Michael D. | CEO & President | Jan 02 '24 | Option Exercise | 18.80 | 2,904 | 54,595 | 2,904 | Jan 04 |
| Amandla MK Trust | 10% Owner | Jan 02 '24 | Sale | 40.31 | 201,100 | 8,106,246 | 3,958,715 | Jan 04 |
| Amandla MK Trust | 10% Owner | Dec 14 '23 | Sale | 41.59 | 600 | 24,954 | 4,159,815 | Dec 14 |